TITLE:
Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals

CONDITION:
HIV Infections

INTERVENTION:
Alvircept sudotox

SUMMARY:

      To investigate the safety and tolerance of an increasing number of infusions per week of
      alvircept sudotox ( sCD4-PE40; soluble CD4-Pseudomonas exotoxin ) at a fixed dose when
      administered to HIV-1-infected individuals. To investigate the effect of sCD4-PE40 on the
      following parameters: T lymphocyte subsets, plasma HIV RNA and cellular HIV proviral DNA in
      PBMC and CD4 cells, p24 levels, serum beta-2 microglobulin, and neopterin levels.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

        Patients must have:

          -  HIV positivity confirmed by Western blot.

          -  CD4 count of 100 - 500 cells/mm3 on a morning draw within 3 weeks prior to study
             entry.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms and conditions are excluded:

          -  Concurrent neoplasms other than basal cell carcinoma of the skin, in situ carcinoma
             of the cervix, or nondisseminated Kaposi's sarcoma.

          -  Hemophilia or other clotting disorders.

          -  Major organ allograft.

          -  Significant cardiac, hepatic, renal, or CNS disease.

        Prior Medication:

        Excluded:

          -  Antiretroviral agents within 2 months prior to study entry.

          -  Known anti-HIV medication within 60 days prior to study entry.

          -  Prior immunomodulators (e.g., systemic steroids, interferons, or interleukins) or
             other chemotherapy.

        Prior Treatment:

        Excluded:

          -  Prior radiation therapy. Active substance abuse.
      
